Hashimoto's thyroiditis study probes hidden inflammation link
NCT ID NCT07453290
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares levels of two proteins, Klotho and FGF23, in 150 adults with Hashimoto's thyroiditis versus healthy controls. The goal is to see if these proteins are linked to inflammation in the disease. No treatment is given—only blood samples are taken.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal a new biological pathway involved in Hashimoto's thyroiditis, potentially pointing toward future treatment targets.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures biomarkers and cannot prove cause or lead directly to a therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult participants aged 18-65 years will be recruited from the endocrinology outpatient clinic of a tertiary care center. The study population will consist of patients diagnosed with Hashimoto's thyroiditis and age- and sex-matched healthy controls without thyroid or systemic autoimmune disease. All participants will undergo baseline clinical evaluation and venous blood sampling for measurement of soluble α-Klotho and FGF23 levels, along with routine laboratory parameters.
- Ages
-
18 to 80 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Adults aged 18-65 years Ability to provide written informed consent Hashimoto group: Diagnosis of Hashimoto's thyroiditis based on positive anti-thyroid peroxidase (anti-TPO) and/or anti-thyroglobulin (anti-TG) antibodies with compatible clinical/ultrasound findings (as available) Control group: No history of thyroid disease or autoimmune disease; normal thyroid function tests (TSH and free T4 within reference range) Exclusion Criteria: Pregnancy or breastfeeding Known chronic kidney disease (eGFR \< 60 mL/min/1.73 m²) Active infection or acute inflammatory condition within the past 4 weeks Known malignancy under active treatment Chronic inflammatory/autoimmune disease other than Hashimoto's thyroiditis (e.g., rheumatoid arthritis, SLE, IBD) Use of systemic glucocorticoids or immunosuppressive therapy within the past 3 months Known parathyroid disease or disorders of calcium/phosphate metabolism Current use of medications strongly affecting mineral metabolism (e.g., phosphate binders, active vitamin D analogs)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autoimmune thyroiditis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.